WO2012068531A3 - Novel compositions and uses of anti-hypertension agents for cancer therapy - Google Patents

Novel compositions and uses of anti-hypertension agents for cancer therapy Download PDF

Info

Publication number
WO2012068531A3
WO2012068531A3 PCT/US2011/061510 US2011061510W WO2012068531A3 WO 2012068531 A3 WO2012068531 A3 WO 2012068531A3 US 2011061510 W US2011061510 W US 2011061510W WO 2012068531 A3 WO2012068531 A3 WO 2012068531A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer therapy
novel compositions
cancer
compositions
hypertension agents
Prior art date
Application number
PCT/US2011/061510
Other languages
French (fr)
Other versions
WO2012068531A2 (en
Inventor
Rakesh Kumar Jain
Yves Boucher
Vikash Pal Singh Chauhan
Benjamin Diop-Frimpong
Stephen Krane
Alan L. Crane
Robert Samuel Langer
Original Assignee
The General Hospital Corporation
Xtuit Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The General Hospital Corporation, Xtuit Pharmaceuticals, Inc. filed Critical The General Hospital Corporation
Priority to JP2013540082A priority Critical patent/JP2014505666A/en
Priority to CN201180065389.2A priority patent/CN103561726A/en
Priority to RU2013127625/15A priority patent/RU2013127625A/en
Priority to EP11841427.5A priority patent/EP2640359A4/en
Priority to CA2817250A priority patent/CA2817250A1/en
Priority to AU2011329638A priority patent/AU2011329638C1/en
Publication of WO2012068531A2 publication Critical patent/WO2012068531A2/en
Priority to US13/834,094 priority patent/US20130287688A1/en
Publication of WO2012068531A3 publication Critical patent/WO2012068531A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances

Abstract

Methods and compositions for improving the delivery and/or efficacy of cancer therapeutics are disclosed. Methods and compositions for treating or preventing a cancer (e.g., a solid tumor such as a desmoplastic tumor) by administering to a subject an antihypertensive agent, as a single agent or combination with a cancer therapeutic agent (for example, a therapeutic agent ranging in size from a large nanotherapeutic to a low molecular weight chemotherapeutics and/or oxygen radical) are disclosed.
PCT/US2011/061510 2010-11-18 2011-11-18 Novel compositions and uses of anti-hypertension agents for cancer therapy WO2012068531A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2013540082A JP2014505666A (en) 2010-11-18 2011-11-18 Antihypertensive composition and use for cancer treatment
CN201180065389.2A CN103561726A (en) 2010-11-18 2011-11-18 Novel compositions and uses of anti-hypertension agents for cancer therapy
RU2013127625/15A RU2013127625A (en) 2010-11-18 2011-11-18 NEW COMPOSITIONS AND APPLICATIONS OF ANTIHYPERTENSIVE MEDICINES FOR CANCER THERAPY
EP11841427.5A EP2640359A4 (en) 2010-11-18 2011-11-18 Novel compositions and uses of anti-hypertension agents for cancer therapy
CA2817250A CA2817250A1 (en) 2010-11-18 2011-11-18 Novel compositions and uses of anti-hypertension agents for cancer therapy
AU2011329638A AU2011329638C1 (en) 2010-11-18 2011-11-18 Novel compositions and uses of anti-hypertension agents for cancer therapy
US13/834,094 US20130287688A1 (en) 2010-11-18 2013-03-15 Novel compositions and uses of anti-hypertension agents for cancer therapy

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41519210P 2010-11-18 2010-11-18
US61/415,192 2010-11-18
US201161438240P 2011-01-31 2011-01-31
US61/438,240 2011-01-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/834,094 Continuation-In-Part US20130287688A1 (en) 2010-11-18 2013-03-15 Novel compositions and uses of anti-hypertension agents for cancer therapy

Publications (2)

Publication Number Publication Date
WO2012068531A2 WO2012068531A2 (en) 2012-05-24
WO2012068531A3 true WO2012068531A3 (en) 2013-11-28

Family

ID=46084685

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/061510 WO2012068531A2 (en) 2010-11-18 2011-11-18 Novel compositions and uses of anti-hypertension agents for cancer therapy

Country Status (7)

Country Link
EP (1) EP2640359A4 (en)
JP (2) JP2014505666A (en)
CN (1) CN103561726A (en)
AU (1) AU2011329638C1 (en)
CA (1) CA2817250A1 (en)
RU (2) RU2013127625A (en)
WO (1) WO2012068531A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2260874A1 (en) 2003-01-06 2010-12-15 Angiochem Inc. Aprotinin analogs as carriers across the blood-brain barrier
EP2433653B1 (en) 2005-07-15 2019-06-05 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8710013B2 (en) 2008-04-18 2014-04-29 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
WO2010043049A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
BRPI0920209A2 (en) 2008-10-15 2015-12-22 Angiochem Inc conjugates of glp-1 agonists and their uses
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8853353B2 (en) 2008-12-17 2014-10-07 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
MX2011011023A (en) 2009-04-20 2012-01-20 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog.
BRPI1015918A2 (en) 2009-07-02 2019-09-24 Angiochem Inc multimeric peptide conjugates and uses thereof
EP2836234B1 (en) 2012-04-12 2019-06-12 Yale University Vehicles for controlled delivery of different pharmaceutical agents
AU2013259772A1 (en) * 2012-05-07 2014-12-04 Massachusetts Institute Of Technology Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2014054798A1 (en) 2012-10-04 2014-04-10 独立行政法人国立循環器病研究センター Drug for inhibiting malignant tumor metastasis
EP2914263A4 (en) * 2012-11-02 2016-04-27 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
WO2014129914A1 (en) * 2013-02-22 2014-08-28 Auckland Uniservices Limited Methods of treatment
US8975290B2 (en) 2013-03-01 2015-03-10 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
WO2014134621A2 (en) * 2013-03-01 2014-09-04 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
WO2014168191A1 (en) * 2013-04-10 2014-10-16 公立大学法人奈良県立医科大学 Prophylactic and/or therapeutic agent for hepatocellular carcinoma
WO2015066535A1 (en) * 2013-11-01 2015-05-07 Yale University Modular particles for immunotherapy
US9833431B2 (en) * 2013-11-01 2017-12-05 Pitney Pharmaceuticals Pty Limited Pharmaceutical combinations for the treatment of cancer
RU2017140777A (en) * 2015-04-25 2019-05-28 Дзе Дженерал Хоспитал Корпорейшн COMBINED THERAPY WITH ANTIFUGETACTIC MEANS AND IMMUNOTHERAPEUTIC MEANS AND COMPOSITIONS FOR CANCER TREATMENT
CN107921143B (en) 2015-06-15 2021-11-19 安吉奥开米公司 Method for treating leptomeningeal carcinomatosis
CN105326812A (en) * 2015-10-28 2016-02-17 南昌大学 Sorafenib solid lipid nanoparticles and preparation method thereof
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
EP3505165A4 (en) * 2016-08-26 2020-05-20 Tetsuji Okuno Fine nano-sized medicinal agent and use thereof
TW201815418A (en) * 2016-09-27 2018-05-01 Vertex Pharma Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors
CN108358995B (en) * 2017-01-25 2021-07-06 四川大学 CP-iRGD polypeptide, iDPP nanoparticle, drug-loaded compound and preparation method and application thereof
RU2724398C1 (en) * 2019-09-03 2020-06-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный медицинский университет" Министерства здравоохранения Российской Федерации Method for determining aggressiveness of lung cancer
CN115066231A (en) * 2019-12-13 2022-09-16 麻省理工学院 Synthetic tissue barrier and uses thereof
EP3842099A1 (en) * 2019-12-23 2021-06-30 Albert-Ludwigs-Universität Freiburg Use of losartan for the treatment of fibrotic diseases, in particular epidermolysis bullosa
CN112933235A (en) * 2021-04-07 2021-06-11 北京蛋白质组研究中心 Application of compound targeting SOAT1 protein in preparation of drugs for preventing and/or treating liver cancer
CN115317627B (en) * 2022-08-26 2023-10-24 江西中医药大学 Application of ABT-510 peptide in preparation of tumor imaging agent

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010019715A1 (en) * 1997-09-18 2001-09-06 Idec Pharmaceuticals Corporation Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
US20070129331A1 (en) * 2004-04-20 2007-06-07 Rnd Pharmaceuticals, Inc. Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives
US20080063724A1 (en) * 2005-02-18 2008-03-13 Desai Neil P Methods and compostions for treating proliferative diseases
US20090012052A1 (en) * 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
US20090220588A1 (en) * 2008-02-21 2009-09-03 Massachusetts Institute Of Technology Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
PL174721B1 (en) 1992-11-13 1998-09-30 Idec Pharma Corp Monoclonal antibody anty-cd2
US6719977B1 (en) 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
DE10144980B4 (en) 2001-09-12 2004-06-03 Webasto Vehicle Systems International Gmbh Guide device for a lid of a vehicle roof to be opened
WO2006014626A2 (en) 2004-07-19 2006-02-09 Celator Pharmaceuticals, Inc. Partuculate constructs for release of active agents
TWI386225B (en) 2004-12-23 2013-02-21 Alcon Inc Rnai inhibition of ctgf for treatment of ocular disorders
WO2006077901A1 (en) 2005-01-20 2006-07-27 Shionogi & Co., Ltd. Ctgf expression inhibitor
ES2905923T3 (en) 2005-02-08 2022-04-12 Genzyme Corp TGFbeta antibodies
EP1993611A4 (en) 2006-03-16 2013-05-22 Alnylam Pharmaceuticals Inc RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
US8613951B2 (en) 2008-06-16 2013-12-24 Bind Therapeutics, Inc. Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
EP2285350B1 (en) 2008-06-16 2017-11-15 Pfizer Inc Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles
SI2774608T1 (en) 2008-06-16 2020-02-28 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
EA201100765A1 (en) 2008-12-15 2012-04-30 Бинд Биосаиэнсис Long-term circulation nanoparticles
DE102009002623A1 (en) 2009-04-24 2010-11-04 BSH Bosch und Siemens Hausgeräte GmbH Program selector for a domestic appliance, in particular for a washing machine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010019715A1 (en) * 1997-09-18 2001-09-06 Idec Pharmaceuticals Corporation Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
US20070129331A1 (en) * 2004-04-20 2007-06-07 Rnd Pharmaceuticals, Inc. Pharmaceutical compositions and methods of use of lipophilic, silicon-substituted, cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs and derivatives
US20080063724A1 (en) * 2005-02-18 2008-03-13 Desai Neil P Methods and compostions for treating proliferative diseases
US20090012052A1 (en) * 2006-11-09 2009-01-08 Ore Pharmaceuticals Inc. Method for treating er+ breast cancer
US20090220588A1 (en) * 2008-02-21 2009-09-03 Massachusetts Institute Of Technology Simultaneous Delivery of Receptors and/or Co-Receptors for Growth Factor Stability and Activity
US20100029734A1 (en) * 2008-05-06 2010-02-04 Ore Pharmaceuticals Inc. Methods for breast cancer screening and treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2640359A4 *

Also Published As

Publication number Publication date
JP2017101056A (en) 2017-06-08
EP2640359A4 (en) 2015-11-04
JP2014505666A (en) 2014-03-06
AU2011329638B2 (en) 2016-10-13
RU2018102375A (en) 2019-02-21
EP2640359A2 (en) 2013-09-25
AU2011329638C1 (en) 2017-04-27
CN103561726A (en) 2014-02-05
CA2817250A1 (en) 2012-05-24
AU2011329638A1 (en) 2013-05-30
WO2012068531A2 (en) 2012-05-24
RU2013127625A (en) 2014-12-27

Similar Documents

Publication Publication Date Title
WO2012068531A3 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
PH12016502066A1 (en) Methods of treating bladder cancer
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
MX342951B (en) Therapeutically active compositions and their method of use.
WO2010111406A3 (en) Purine derivatives useful as anti - cancer agents
WO2012024530A3 (en) Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
WO2012009406A3 (en) Gold particles and methods of making and using the same in cancer treatment
MX360404B (en) Compounds for inhibiting cell proliferation in egfr-driven cancers.
NZ595372A (en) Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
MX2019000225A (en) Compositions and methods for treatment of autoimmune and other disease.
WO2011050302A3 (en) Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
TN2012000108A1 (en) Sustituted (heteroarylmethyl) thiohydantoins as anticancer drugs
MX2014002171A (en) Combination treatments for hepatitis c.
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
WO2009114703A3 (en) Combination therapy for the treatment of cancer
MX2020014208A (en) Optimised subcutaneous therapeutic agents.
GB2489382A (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
WO2012040331A3 (en) Multistage nanoparticles
WO2012078867A3 (en) Cycloalkyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
IN2015DN01328A (en)
MX370688B (en) Compositions and methods for drug-sensitization or inhibition of a cancer cell.
WO2013096335A8 (en) ADMINISTRATION OF AN ANTAGONIST OF α5β1 FOR ANTI-ANTIOGENESIS AND CANCER TREATMENT
WO2012061012A3 (en) 4-amino-2h-pyran-2-one analogs as anticancer agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11841427

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2817250

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013540082

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2011329638

Country of ref document: AU

Date of ref document: 20111118

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011841427

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013127625

Country of ref document: RU

Kind code of ref document: A